Generic drug growth may slow with approval of more complex medicines

Generic drug growth may slow with approval of more complex medicines

We’ve talked on this website about how the increasing use of generic drugs is a net-positive for healthcare consumers. The same commonly prescribed drugs have dropped precipitously in price in recent years as they became available in generic form.

In the near term, though, we may begin to see that trend soften a bit. Not because prescribing behaviors are changing, but rather because most of the easy wave of generic creation has already passed. 

And, going forward, generic drugs may be more difficult to manufacture, due to the nature of the medicines they aim to replicate.

Why will the growth of generic drugs slow?

According to the non-partisan Congressional Budget Office (CBO) in its landmark 2022 study “Prescription Drugs: Spending, Use, and Prices,” “The use of generic drugs may not increase much further for two reasons: 

  • First, generic drugs are used extensively. (Those drugs represent 90 percent of all prescriptions.) 
  • Second, newer drugs are more likely to be biologics (drugs that are produced from living organisms). Those drugs are more complex and harder to manufacture or replicate than small-molecule drugs. Consequently, there may be fewer generics developed from them when their patents expire. 

“Manufacturing a biologic with the same active molecule—called a biosimilar—introduces an additional layer of complexity compared with small-molecule drugs.

“Biosimilars are necessarily created from different cell lines than the originals, so they are not identical at the molecular level. As a result—unlike for generic versions of small-molecule drugs—noninnovator firms (that is, manufacturers of generic or biosimilar drugs) typically need to run clinical trials to demonstrate that their biosimilars are not meaningfully different from the reference biologic product.”

Coupons and discount programs may thwart generic adoption in the long run

Additionally, a trend we’ve discussed here previously – the creation of coupon or discount programs by pharmaceutical manufacturers – could potentially disincentivize generic creation and adoption in the future.

The CBO notes, “Drug manufacturers have been able to partly neutralize insurance plans’ ability to steer their enrollees toward generic drugs by issuing coupons directly to consumers. Drug coupons make expensive therapies more affordable and increase manufacturers’ unit sales. When a coupon induces an enrollee to choose a brand-name drug over a generic, it increases the cost to insurers because they then must cover the more expensive brand-name drug for that enrollee. 

Coupon programs offered by manufacturers have become more prevalent over time: Whereas in 2009 manufacturers issued coupons for fewer than 100 brand-name drugs, by 2015 more than 700 drugs were covered by coupons.

In 2022, the non-partisan Congressional Budget Office (CBO) of the United States issued a landmark study that tracks the use of prescription drugs, their costs and their benefits.

In the overview article, we look at the general trends identified by the CBO over the past 40 years. Subsequent articles dive in deeper        

Read more:

VativoRx Joins MHA: A New Chapter Begins

The world of healthcare is dynamic, continuously evolving with new challenges and opportunities. At VativoRx, we’ve always believed in the power of innovation, collaboration, and dedication to ensure that we provide the best rebate management solutions in the industry. Today, we’re thrilled to announce our latest milestone: VativoRx is now an official associate member of the Michigan Health & Hospital Association (MHA)!

Read More »

Unveiling the Future: Navigating the Evolving Landscape of 340B Rebates.

The 340B Drug Pricing Program, established in 1992, has been a crucial component of the healthcare system, dedicated to assisting eligible healthcare organizations in serving vulnerable patient populations by granting them access to discounted drugs. At the heart of this program are the 340B rebates, which enable qualifying entities such as safety-net hospitals, community health centers, and other eligible providers to acquire medications at significantly reduced prices.

Read More »
Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »

Biosimilars — Similar But Not Identical

You may have never heard of biosimilar drugs and that’s probably because they are not commonly prescribed in the United States even though they have been around for over 20 years. So, what are biosimilar drugs? A biosimilar drug is no different in terms of safety and effectiveness than a biologic product, also known as a reference product, and while highly similar it is not identical.

Read More »

Lower Cost Prescription Drugs from Canada, Is It Legal?

In the early 2000s, the FDA set up guidelines in the Regulatory Procedures Manual (RPM) that permitted prescription drugs to be imported from other countries if the patient met very strict guidelines. Just stating that the patient needed the drug due to cost savings was not a justification to obtain the drug.

Read More »